Practical Radiation Oncology最新文献

{"title":"Prostate Specific Membrane Antigen Positron Emission Tomography in Management of Vestibular Schwannoma.","authors":"Pavnesh Kumar, Kyle Wu, Daniel Prevedello, Edward Dodson, Jana Ivanidze, Divya Yadav, Rituraj Upadhyay, Jonathan P S Knisely, Oliver Adunka, TaeLor Jones, Evan M Thomas, Raju R Raval, Sasha Beyer, Bingfeng Tang, Joshua D Palmer","doi":"10.1016/j.prro.2025.03.004","DOIUrl":"10.1016/j.prro.2025.03.004","url":null,"abstract":"<p><p>Vestibular schwannomas (VSs) are benign tumors arising from vestibulocochlear nerve Schwann cells. Single or multifractional stereotactic radiation therapy (SRT) is commonly used for treatment of these tumors, and accurate target delineation is critical for the focused radiation delivery, maximizing tumor control while minimizing toxicity. Contrast-enhanced magnetic resonance imaging (MRI) is the gold standard for diagnosis, monitoring of VS and is critical in precise target delineation for SRT planning. Prostate specific membrane antigen (PSMA) positron emission tomography (PET) has established clinical utility for diagnosis and monitoring of prostate cancer. However, other central nervous system neoplasms, including VS, have also been found to be PSMA tracer avid. We present the first clinical use of PSMA PET for SRT in a patient with VS who was unable to undergo MRI.</p>","PeriodicalId":54245,"journal":{"name":"Practical Radiation Oncology","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143674808","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prospective Peer Review in Radiation Oncology: Analysis of Protocol Deviations at a Large Multicenter Institution to Improve Patient Safety.","authors":"Manav Shah, Ajay Kapur, Louis Potters, Leila T Tchelebi","doi":"10.1016/j.prro.2025.03.001","DOIUrl":"10.1016/j.prro.2025.03.001","url":null,"abstract":"<p><strong>Purpose: </strong>Peer review is essential for radiation therapy (RT) quality assurance and recent studies show that peer review upstream of treatment planning is feasible and can improve RT quality. Herein, we describe protocol deviations detected by our peer review process by the type of deviation, disease site, and physician characteristics.</p><p><strong>Methods and materials: </strong>Once contoured, cases within our department undergo prospective peer review with each case assigned a grade (A, B, or C). \"A\" cases require no changes, whereas \"B\" and \"C\" cases have protocol deviations requiring minor or major modification, respectively, prior to treatment planning. We reviewed all radiation cases with curative intent from 2017 to 2022. We analyzed cases receiving a B score by type of protocol deviation, disease site, and physician characteristics. The 2-proportion Z-test was performed to determine differences in the proportion of B scores.</p><p><strong>Results: </strong>Thirteen thousand ninety-one curative cases underwent peer review across our institution; 58.6% of cases received an \"A,\" 41.3% received a \"B,\" and 0.1% received a \"C.\" Common errors in cases receiving a B score were a mismatch between the prescription and directive (34.2%) or a deviation in the planning target volume (32.8%). The disease sites that accounted for the largest volume of all B scores were head and neck (20.2%), prostate (13.2%), breast (9.1%), and lung (7.9%). Generalists had a greater percentage of B scores compared to specialists (46.9% vs 34.3%, P < .0002). No significant difference in B scores was observed between tenure and nontenure physicians (40.5% vs 42.2%, P = .0511).</p><p><strong>Conclusions: </strong>Peer-review contour rounds were performed on 100% of curative cases where 41% required modification prior to treatment planning, highlighting the importance of prospective contour peer review for all patients to catch discrepancies upstream of treatment planning. Implementing peer review in radiation oncology can mitigate common deviations in RT planning, irrespective of disease site or physician expertise.</p>","PeriodicalId":54245,"journal":{"name":"Practical Radiation Oncology","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143671854","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Feasibility and Benefits of a Simplified Physics Direct Patient Care Protocol.","authors":"Cassandra K K Stambaugh, Kathryn E Huber, John E Mignano, Elizabeth Meyer, Christopher S Melhus","doi":"10.1016/j.prro.2025.02.010","DOIUrl":"10.1016/j.prro.2025.02.010","url":null,"abstract":"<p><strong>Purpose: </strong>To investigate the benefits and challenges of implementing a medical physics consult program in a small clinic.</p><p><strong>Methods and materials: </strong>A simplified physics direct patient care (SPDPC) protocol was developed based on previously described programs. The program was streamlined to 1 consult with a physicist during a 30-minute time block. Nonemergent patients were offered the program on the day of external beam simulation and, if they indicated interest in 1 of 3 consults (virtual, day of sim, first day of treatment) via an initial survey, they took the short form of the Spielberger State-Trait Anxiety Inventory (STAI-6). At consult, the physicist provided a brief overview of treatment planning and quality assurance, answered questions, and provided a tour of the treatment room (virtual or in-person). Patients repeated the STAI-6, answered 2 emotional check-in and 3 technical satisfaction questions after the consult, and then repeated the STAI-6, 3 technical satisfaction, and 1 overall satisfaction question at the end of treatment (EOT).</p><p><strong>Results: </strong>The SPDPC clinical trial ran for 2 years. Two hundred patients were offered participation and 45% (n = 90) enrolled. Of them, 67% chose a consult in person on their first day of treatment. Seventy-eight patients completed the consult and 65 completed the EOT survey. The anxiety score was (mean ± standard deviation) 32.1 ± 12.8 at baseline, 27.5 ± 12.0 after the medical physics consult, and 26.7 ± 9.0 at the EOT. The change in mean anxiety score from enrollment to after the medical physics consult was statistically significant (P = .0004), and the change from consult to EOT was not significant. The mean technical satisfaction score was evaluated on a 4-point Likert scale. After the medical physics consult, the mean technical satisfaction score was 3.82 ± 0.51 and at EOT 3.92 ± 0.19. There was no statistically significant difference between these 2 time points.</p><p><strong>Conclusions: </strong>Establishing a new clinical role for medical physicists in a small clinic can be challenging because of staffing resources and time restrictions. A SPDPC protocol allows smaller clinics to provide medical physics consults despite these challenges, while maintaining a similar positive impact to larger programs on the patient and their care experience.</p>","PeriodicalId":54245,"journal":{"name":"Practical Radiation Oncology","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143574676","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Practical Approach to Computed Tomography Guided Online Adaptive Radiation Therapy for Abdominopelvic Tumors.","authors":"David P Horowitz, Yi-Fang Wang, Albert Lee, Adam C Riegel, Jared Pasetsky, Carl Elliston, Catherine Spina, Israel Deutsch, Zahra Ghiassi-Nejad, Yading Yuan, Michael Price, Lisa A Kachnic","doi":"10.1016/j.prro.2025.02.011","DOIUrl":"10.1016/j.prro.2025.02.011","url":null,"abstract":"","PeriodicalId":54245,"journal":{"name":"Practical Radiation Oncology","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143574677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Single Fraction Radiosurgical Tolerance of Brainstem, Trigeminal Nerve, and Meckel's Cave for Facial Numbness","authors":"Krishna C. Monroe ,&nbsp;Ronald L. Hammers MD ,&nbsp;Olivier C. Blasi MS ,&nbsp;Richard C. Mallory MS ,&nbsp;Alan T. Monroe MD","doi":"10.1016/j.prro.2024.08.011","DOIUrl":"10.1016/j.prro.2024.08.011","url":null,"abstract":"<div><h3>Purpose</h3><div>This article reviews toxicity outcomes for a series of patients treated with stereotactic radiosurgery for trigeminal neuralgia, focusing on dose to the brainstem, trigeminal nerve, and Meckel's cave as possible explanatory variables for the development of the most common posttreatment neuropathy, facial numbness.</div></div><div><h3>Methods and Materials</h3><div>A retrospective review of 136 cases treated with CyberKnife radiosurgery for trigeminal neuralgia was performed. Dose was initially (cohort 1) prescribed to 57 to 64 Gy covering a 6-mm cylindrical shaped target volume ≥2 mm from the dorsal root entry zone. Subsequently, a deliberate change to isocentric treatment planning occurred, resulting in delivery of 85 Gy to a spherical target (cohort 2). Brainstem, trigeminal nerve, and Meckel's cave were contoured, and a variety of dosimetric and clinical factors were analyzed for association with development of treatment-related facial numbness.</div></div><div><h3>Results</h3><div>Treatment-related numbness occurred in 59 of 136 (43%) patients and did not differ between the treatment cohorts. Fifty-two patients experienced Barrow Neurological Institute (BNI) grade II toxicity, and 7 patients experienced BNI grade III toxicity. Time to numbness was 16.0 months for cohort 1 and 10.4 months for cohort 2 (<em>P</em> = .184). The median brainstem maximum dose was 26.1 Gy, ranging from 4.2 Gy to 57.3 Gy. Maximum dose to the trigeminal nerve was 85 Gy. Mean trigeminal nerve dose was 47.3 Gy. The median Meckel's cave maximum and mean doses were 26.0 Gy and 6.8 Gy, respectively. No definitive upper limit dose threshold was detected for the structures analyzed, but trends were noted for maximum trigeminal nerve dose of 85 Gy (<em>P</em> = .083) and for prescription dose (<em>P</em> = .057) and trigeminal nerve V40 (<em>P</em> = .077) in the type I subset.</div></div><div><h3>Conclusions</h3><div>Brainstem, trigeminal nerve, and Meckel's cave tolerated doses within the range delivered. Discussion of the literature is provided to guide treatment planning and management.</div></div>","PeriodicalId":54245,"journal":{"name":"Practical Radiation Oncology","volume":"15 2","pages":"Pages e124-e130"},"PeriodicalIF":3.4,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142480645","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reducing Patient Care Delays in Radiation Oncology Via Optimization of Insurance Preauthorization","authors":"Maxwell Tran MD ,&nbsp;Bhisham Chera MD, FASTRO ,&nbsp;Kevin Shrake MD ,&nbsp;Bradley Depaoli MD ,&nbsp;Edward Duffy III MD ,&nbsp;Michael Hall MD ,&nbsp;Justin Steinman DO ,&nbsp;Stephanie Myers MD ,&nbsp;Osagie Igiebor MD ,&nbsp;Jay Callahan ,&nbsp;Daniel McDonald MS ,&nbsp;Jennifer Harper MD ,&nbsp;Samuel Lewis Cooper MD","doi":"10.1016/j.prro.2024.10.002","DOIUrl":"10.1016/j.prro.2024.10.002","url":null,"abstract":"<div><h3>Purpose</h3><div>Difficulties and delays in insurance preauthorization (preauth) can negatively impact patient care, resulting in postponing, modifying, or even canceling radiation therapy for patients. We aimed to perform a root cause analysis for preauth delays in our department and implement solutions to optimize our workflow. Our primary objectives were to decrease the mean time for clinical treatment plan (CTP) completion and the number of cases delayed/denied by 50% each.</div></div><div><h3>Methods and Materials</h3><div>We performed a root cause analysis for preauth delays and used the Plan, Do, Study, Act, and A3 quality improvement methods. We sampled ∼2 cases per disease site (19 cases from July to August 2022) to determine the baseline. Countermeasures included (1) optimizing our CTP templates per disease site to contain the specific clinical information required for preauth, (2) formalizing earlier completion of CTPs in our Care Path, and (3) formalizing the preauth workflow in our Care Path. We tracked various metrics, including the mean time for CTP completion, the percentage usage of our Care Path, the percentage usage of revised CTP templates, the mean time until preauth was initiated and completed, and the percentage of cases delayed/denied. Two-tailed <em>t</em> tests and χ² tests were used to generate <em>P</em> values comparing mean values and percentages, respectively.</div></div><div><h3>Results</h3><div>A total of 495 patients completed computed tomography simulation in our department between October 2022 and February 2023. The mean time for CTP completion (day 0 = day of computed tomography simulation scheduling) improved from 16 days at baseline to 4 days (<em>P</em> &lt; .001). Care Path usage improved from 16% to 97% (<em>P</em> &lt; .001), as did the usage of our revised CTP templates, from 0% to 97% (<em>P</em> &lt; .001). The mean time from insurance preauth initiation to completion improved from 5 days to 1 day. The percentage of cases that were delayed/denied was reduced significantly from 32% to 8% (<em>P</em> &lt; .001).</div></div><div><h3>Conclusions</h3><div>Improving timeliness and details of CTP documentation and preauth by using our Care Path and optimizing CTP templates improved the efficiency of insurance preauth completion and reduced the number of cases delayed/denied.</div></div>","PeriodicalId":54245,"journal":{"name":"Practical Radiation Oncology","volume":"15 2","pages":"Pages e100-e108"},"PeriodicalIF":3.4,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142570230","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Excluding Upper Axillary Level 1 in Regional Nodal Irradiation Does Not Increase Axillary Recurrence Risk in Patients With Breast Cancer","authors":"Hwa Kyung Byun MD, PhD ,&nbsp;Hyung Seok Park MD, PhD ,&nbsp;Seo Hee Choi MD ,&nbsp;Seho Park MD, PhD ,&nbsp;Jee Suk Chang MD, PhD ,&nbsp;Ik Jae Lee MD, PhD ,&nbsp;Yong Bae Kim MD, PhD","doi":"10.1016/j.prro.2024.08.010","DOIUrl":"10.1016/j.prro.2024.08.010","url":null,"abstract":"<div><h3>Purpose</h3><div>The optimal extent of regional nodal irradiation (RNI) in postoperative radiation therapy for breast cancer, particularly regarding axillary level 1 (AXL1), remains uncertain. This study aimed to compare clinical outcomes between extensive RNI including the entire axilla and limited RNI excluding the upper AXL1 in patients with breast cancer.</div></div><div><h3>Methods and Materials</h3><div>A retrospective analysis included 1780 women with nonmetastatic unilateral breast cancer who underwent RNI during postoperative radiation therapy between 2007 and 2018. Patients were classified into extensive and limited RNI groups based on the upper AXL1 inclusion in the radiation field. Propensity-score matching yielded a cohort of 1020 patients. Noninferiority of limited RNI compared with extensive RNI was assessed with a defined margin of ≤2% in the 5-year axillary recurrence rate.</div></div><div><h3>Results</h3><div>After a median follow-up of 67.9 months, the 5-year axillary recurrence rates were similar between extensive and limited RNI groups (1.2% vs 1.6%; <em>P</em>_log-rank= .790). Limited RNI demonstrated noninferiority with a 0.4% difference (95% confidence interval, –1.1% to 1.9%; <em>P</em>_{noninferiority}= .019). Disease-free survival (87.9% vs 91.5%; <em>P</em>_log-rank= .122) and overall survival (94.1% vs 96.9%; <em>P</em>_log-rank= .260) at 5 years were not significantly different between extensive and limited RNI groups. Multivariable analysis revealed that lymphovascular invasion (hazard ratio [HR], 5.17; <em>P</em> = .02) and negative hormone receptor status (HR, 11.73; <em>P</em> = .002) were associated with a higher risk of axillary recurrence, whereas limited RNI showed no significant association (HR, 1.35; <em>P</em> = .652). Subgroup analysis demonstrated that extensive RNI did not improve axillary control in patients with lymphovascular invasion, hormone receptor negativity, positive lymph node metastasis, or a small number of nodes removed.</div></div><div><h3>Conclusions</h3><div>Limited RNI, excluding the upper AXL1 from the radiation field, demonstrated axillary recurrence rates comparable with those of extensive RNI in patients with breast cancer. The study suggests that extensive RNI may not provide additional therapeutic benefits, whereas limited RNI appears to be a valid option for regional control.</div></div>","PeriodicalId":54245,"journal":{"name":"Practical Radiation Oncology","volume":"15 2","pages":"Pages 144-154"},"PeriodicalIF":3.4,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142373571","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of Pathologic Tumor Necrosis of Conventional Versus Ultrahypofractionated Preoperative Radiation Therapy in Localized Extremity Soft Tissue Sarcoma and Its Correlation With Clinical Outcomes","authors":"Hanis Hanafi MD ,&nbsp;Carolyn R. Freeman MD ,&nbsp;James Tsui MD ,&nbsp;Paul Ramia MD ,&nbsp;Robert Turcotte MD ,&nbsp;Ahmed Aoude MD ,&nbsp;Anthony Bozzo MD ,&nbsp;Fabio L. Cury MD","doi":"10.1016/j.prro.2024.10.008","DOIUrl":"10.1016/j.prro.2024.10.008","url":null,"abstract":"<div><h3>Purpose</h3><div>We aimed to determine if ultrahypofractionated radiation therapy (UHYPO-RT) delivering 6 Gy x 5 fractions yields similar tumor necrosis compared with conventional radiation therapy (CONV-RT) with 2 Gy x 25 fractions in soft tissue sarcoma. The clinical significance of tumor necrosis on loco-regional recurrence-free survival (LRFS), distant disease-free survival (DDFS), and overall survival (OS) were assessed.</div></div><div><h3>Methods and Materials</h3><div>Patients with localized soft tissue sarcoma treated with CONV-RT or UHYPO-RT followed by surgery were included. Good response was defined as tumor necrosis ≥90%, and poor response as &lt;90%. The Mann-Whitney <em>U</em> test compared median tumor necrosis. χ² analysis was used for categorical variables. The Kaplan-Meier function estimated LRFS, DDFS, and OS.</div></div><div><h3>Results</h3><div>A total of 64 patients received CONV-RT, and 45 received UHYPO-RT. The median tumor size was 7.0 cm, with the lower extremity being the most common site (55%). Myxofibrosarcoma (39%) and undifferentiated pleomorphic sarcoma (16%) were the most frequent histologies. The median time from radiation therapy to surgery was 35 days. There was a significant difference in median tumor necrosis between CONV-RT and UHYPO-RT, with rates of 40% and 60%, respectively (<em>P</em> = .022). Patients receiving UHYPO-RT had a higher percentage of tumor necrosis at the 90% cutoff, achieving 27% compared with 6% for CONV-RT (<em>P</em> = .003). At a median follow-up of 32 months, 12 patients (9%) experienced loco-regional recurrence, 24 patients (19%) faced distant failure, and 19 patients (15%) died of metastatic disease. Patients with &lt;90% necrosis had higher rates of loco-regional (13% vs 0%, <em>P</em> = .207) and distant failure (25% vs 0%, <em>P</em> = .021). Three-year LRFS was 86% for &lt;90% necrosis and 100% for ≥90% necrosis (<em>P</em> = .160). DDFS was 75% for &lt;90% necrosis versus 100% for ≥90% (<em>P</em> = .036). OS rates were 79% and 93%, respectively (<em>P</em> = .290).</div></div><div><h3>Conclusions</h3><div>Preoperative RT with UHYPO-RT was associated with a higher rate of tumor necrosis ≥90% than CONV-RT. Our data suggest that more extensive necrosis is associated with better clinical outcomes.</div></div>","PeriodicalId":54245,"journal":{"name":"Practical Radiation Oncology","volume":"15 2","pages":"Pages e189-e197"},"PeriodicalIF":3.4,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142559466","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Masthead/Sub page","authors":"","doi":"10.1016/S1879-8500(25)00023-2","DOIUrl":"10.1016/S1879-8500(25)00023-2","url":null,"abstract":"","PeriodicalId":54245,"journal":{"name":"Practical Radiation Oncology","volume":"15 2","pages":"Page A1"},"PeriodicalIF":3.4,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143705177","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PROshot: Dose Escalation for Non-small Cell Lung Cancer, 5-year Outcomes for Prostate Stereotactic Body Radiation Therapy, Optimal Chemotherapy for Oligodendroglioma, and Omitting Sentinel Lymph Node Biopsy in Early Breast Cancer","authors":"Caleb Dulaney MD ,&nbsp;Laura Dover MD, MSPH","doi":"10.1016/j.prro.2025.01.007","DOIUrl":"10.1016/j.prro.2025.01.007","url":null,"abstract":"","PeriodicalId":54245,"journal":{"name":"Practical Radiation Oncology","volume":"15 2","pages":"Pages 113-116"},"PeriodicalIF":3.4,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143705178","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}